Kalaris Therapeutics
KLRS
84 hedge funds and large institutions have $184M invested in Kalaris Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 14 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.12% more ownership
Funds ownership: 1.7% → 1.81% (+0.12%)
0% more funds holding
Funds holding: 84 → 84 (0)
44% less capital invested
Capital invested by funds: $329M → $184M (-$145M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.82M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$4.04M |
| 4 |
JP Morgan Chase
New York
|
+$1.44M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$5.62M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.38M |
| 3 |
EOJOAM
E. Ohman J:or Asset Management
Stockholm,
Sweden
|
-$1.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1,000K |
| 5 |
Rafferty Asset Management
New York
|
-$816K |
KLRS Hedge Fund Activity: Q1 2022 in Review
84 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2022, worth a combined $184M — down 44% from $329M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KLRS positions and 14 closed out — a net gain of 1 holder — while 28 added to existing stakes and 26 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $12.5M. The largest seller was State Street, cutting an estimated $5.62M.
- 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $184M of Kalaris Therapeutics stock for Q1 2022, down 44% quarter-over-quarter.
- 15 funds opened new Kalaris Therapeutics positions in Q1 2022 and 14 closed out, a net change of +1 holder.
- The largest Kalaris Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $12.5M added.
- The largest Kalaris Therapeutics seller in Q1 2022 was State Street, an estimated $5.62M sold.
Based on aggregated 13F filings for Q1 2022.